Measuring Anatomical Outcomes of Anti-VEGF Treatment of Diabetic Macular Edema With Artificial Intelligence

Diabetic macular edema (DME) is the most common cause of visual dysfunction in patients with diabetes, with an estimated worldwide prevalence of 7.4%.1 In addition to its effects on individual quality of life, DME poses a significant economic burden on health care systems.2 As such, identifying the…